Table 2.
Serum levels of biomarkers tested in CRC patients in relation to clinicopathological features of tumor.
| Variable analyzed | No. | ITIH3 (μg/mL) | p value∗ | ITIH4 (μg/mL) | p value∗ |
|---|---|---|---|---|---|
| Median (range) | Median (range) | ||||
| Age | 0.830 | 0.586 | |||
| ≤60 | 48 | 4.429 (2.152–8.170) | 0.205 (0.110–0.592) | ||
| >60 | 53 | 4.370 (2.852–8.070) | 0.213 (0.099–0.415) | ||
| Gender | 0.133 | 0.574 | |||
| Male | 57 | 4.170 (2.152–8.170) | 0.216 (0.106–0.592) | ||
| Female | 44 | 4.577 (2.862–7.098) | 0.203 (0.099–0.422) | ||
| Smoking | 0.183 | 0.452 | |||
| Yes | 58 | 4.204 (2.162–8.170) | 0.204 (0.103–0.592) | ||
| No | 43 | 4.569 (2.152–8.070) | 0.221 (0.099–0.409) | ||
| Alcohol | 0.734 | 0.240 | |||
| Yes | 47 | 4.260 (2.152–8.170) | 0.222 (0.103–0.592) | ||
| No | 54 | 4.411 (2.352–7.098) | 0.207 (0.099–0.421) | ||
| Tumor localization | 0.771 | 0.446 | |||
| Rectum | 34 | 4.266 (2.152–8.170) | 0.206 (0.106–0.429) | ||
| Colon | 67 | 4.385 (2.162–8.070) | 0.211 (0.099–0.592) | ||
| Tumor size | 0.307 | 0.872 | |||
| ≤3 cm | 45 | 4.576 (2.352–8.170) | 0.210 (0.103–0.592) | ||
| >3 cm | 56 | 4.204 (2.152–8.070) | 0.212 (0.099–0.587) | ||
| Tumor stage (AJCC) | 0.404 | 0.278 | |||
| Stage I | 10 | 4.473 (3.820–4.820) | 0.185 (0.110–0.263) | ||
| Stage II | 15 | 4.585 (3.788–8.170) | 0.210 (0.127–0.315) | ||
| Stage III | 19 | 4.207 (2.162–6.898) | 0.213 (0.162–0.587) | ||
| Stage IV | 57 | 4.219 (2.152–8.070) | 0.219 (0.099–0.592) | ||
| Distant metastases | 0.261 | 0.617 | |||
| Nonmetastatic group | 44 | 4.512 (2.162–8.170) | 0.206 (0.110–0.587) | ||
| Metastatic group | 57 | 4.219 (2.152–8.070) | 0.219 (0.099–0.592) | ||
| MSI status | 0.680 | 0.692 | |||
| MSS | 55 | 4.556 (2.162–8.070) | 0.211 (0.099–0.592) | ||
| MSI-H | 8 | 4.401 (2.852–5.265) | 0.232 (0.127–0.409) | ||
| Unknown | 38 | 4.177 (2.152–8.170) | 0.207 (0.103–0.432) |
∗ p < 0.05: statistically significant. CRC: colorectal cancer; ITIH3: inter-alpha-trypsin inhibitor heavy chain H3; ITIH4: inter-alpha-trypsin inhibitor heavy chain H4; MSI: microsatellite instability status; MSS: microsatellite stable; MSI-H: microsatellite instability status high.